Clinical TrialApr 27, 2026, 07:07 AM
ETON Starts Pilot Study for ET-700 in Wilson Disease
AI Summary
Eton Pharmaceuticals, Inc. announced the commencement of a pilot study for its product candidate ET-700. This extended-release formulation of zinc acetate is being developed for the treatment of Wilson disease. The study is designed to compare the efficacy of ET-700 against both Galzin and a placebo.
Key Highlights
- Eton Pharmaceuticals initiated a pilot study for product candidate ET-700.
- ET-700 is an extended-release formulation of zinc acetate.
- The study targets the treatment of Wilson disease.
- ET-700 will be compared against Galzin and a placebo in the study.
Price Impact
More from ETON